

Ref: FOIA Reference 2022/23-124

Royal Stoke University Hospital

Data, Security and Protection Newcastle Road Stoke-on-Trent Staffordshire ST4 6QG

Date: 20th June 2022

Email foi@uhnm.nhs.uk

Dear

I am writing to acknowledge receipt of your email dated 10th June 2022 requesting information under the Freedom of Information Act (2000) regarding Migraine.

The University Hospitals of North Midlands Trust is committed to the Freedom of Information Act 2000.

However, the NHS is facing unprecedented challenges relating to the coronavirus (COVID-19) pandemic at the current time. Understandably, our resources have been diverted to support our front-line colleagues who are working tremendously hard to provide care for our patients, and to those in need of our services.

We strive to be transparent and to work with an open culture. But at this time, whilst care of our patients and the safety of our staff takes precedent, it is likely that responses to some requests for information will be delayed. We apologise for this position in advance, and will endeavour to provide you with as much information as we can, as soon as we are able.

The Information Commissioners Office has recognised the current situation in the NHS.

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 How many patients have been treated with the following drugs in the past 4 months:

- Erenumab (Aimovig) for any disease
- Fremanezumab (Ajovy) for any disease
- Galcanezumab (Emgality) for any disease
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) for migraine ONLY
- A1 See below:
 - Erenumab (Aimovig) for any disease = 18 patients
 - Fremanezumab (Ajovy) for any disease = 195 patients
 - Galcanezumab (Emgality) for any disease = None
 - Botulinum Toxin (i.e., Botox, Dysport, Xeomin) for migraine ONLY = 199
- Q2 I would like to understand the source of funding of Botox and anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality) for migraine. Could you please answer the following questions?







- Does the Trust commission/fund Botulinum Toxin treatment for migraine (Y/N)?
- Does the Trust commission/fund anti-CGRP treatments for migraine (Y/N)?
- In case the Trust actively provides Botulinum Toxin treatment for migraine but does not commission/fund it, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your Trust.
- In case the Trust actively provides anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your Trust.
- A2 See below:
 - Does the Trust commission/fund Botulinum Toxin treatment for migraine = (Y)
 - Does the Trust commission/fund anti-CGRP treatments for migraine = (N)
 - In case the trust actively provides Botulinum Toxin treatment for migraine but does not commission/fund it, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your Trust. = Not applicable
 - In case the Trust actively provides anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your Trust. = Not applicable

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <u>http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx</u>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.







Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via <u>www.ico.org.uk</u>.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,

1 Cohert

Jean Lehnert Data, Security & Protection Manager



